Contact and place of performance
Eugene Jackson
Shreveport 71101
RFQ 36C25625Q1470 Question and Answer Reponses The purpose of this amendment is to: Clarify that this requirement is LPTA for brand name or equal to products. Clarify that all CLIN 0001-4026 are all brand name or equal to products and the OEM for the CLINs listed is Werfen. Address the questions submitted in response to the solicitation question deadline of 3pm 09/09/2025. See below Vendor 1: Question: Would it be po...
View moreThe Department of Veterans Affairs, Network Contract Office 16, has issued solicitation 36C25625Q1470 for the procurement of blood control reagents to be delivered to Shreveport. This requirement is classified under NAICS 325413 for In-Vitro Diagnostic Substance Manufacturing and PSC 6550 for In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. The contract will be awarded on a Lowest Price Technically Acceptable (LPTA) basis for brand name or equal products.
The scope of this acquisition covers items listed in CLINs 0001 through 4026, for which the Original Equipment Manufacturer (OEM) is Werfen. Administrative updates to the solicitation clarified that a duplicate entry for Anti-M reagent was accidental and represents a single requirement rather than two separate CLINs. Responses to this combined synopsis/solicitation are due by September 12, 2025, and the primary point of contact is Eugene Jackson.
As of September 10, 2025, the notice includes three attachments: a solicitation amendment document, an SF-30 Amendment file, and the original solicitation document. These materials incorporate responses to vendor inquiries submitted by the September 9, 2025, question deadline, establishing the technical baseline for the "brand name or equal" products required for blood control testing.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.